Olaratumab - Eli Lilly

Drug Profile

Olaratumab - Eli Lilly

Alternative Names: IMC-3G3; Lartruvo; LY 3012207

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Soft tissue sarcoma
  • Phase I/II Pancreatic cancer
  • Phase I Solid tumours
  • No development reported Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 13 Nov 2017 The Scottish Medicines Consortium accepts olaratumab for routine use by NHS Scotland for the treatment of advanced soft tissue sarcoma
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV, Infusion)
  • 18 Oct 2017 Eli Lilly initiates enrolment in a phase Ib trial for Soft tissue sarcoma (Late-stage disease, Metastatic disease, Combination therapy) in Germany and Italy (IV) (NCT03283696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top